JPWO2021219019A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021219019A5 JPWO2021219019A5 JP2022566337A JP2022566337A JPWO2021219019A5 JP WO2021219019 A5 JPWO2021219019 A5 JP WO2021219019A5 JP 2022566337 A JP2022566337 A JP 2022566337A JP 2022566337 A JP2022566337 A JP 2022566337A JP WO2021219019 A5 JPWO2021219019 A5 JP WO2021219019A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ring
- compound according
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 330
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 53
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 22
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 206010022489 Insulin Resistance Diseases 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000005549 heteroarylene group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 7
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 208000010444 Acidosis Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 6
- 208000003790 Foot Ulcer Diseases 0.000 claims description 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims description 6
- 208000007976 Ketosis Diseases 0.000 claims description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 6
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 6
- 201000010802 Wolfram syndrome Diseases 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 6
- 230000010014 adipocyte dysfunction Effects 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 208000020832 chronic kidney disease Diseases 0.000 claims description 6
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 6
- 208000018631 connective tissue disease Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
- 208000004104 gestational diabetes Diseases 0.000 claims description 6
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 6
- 230000002440 hepatic effect Effects 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 6
- 201000008980 hyperinsulinism Diseases 0.000 claims description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 6
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 6
- 230000004140 ketosis Effects 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 230000000291 postprandial effect Effects 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 208000001381 pseudotumor cerebri Diseases 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 6
- 230000004584 weight gain Effects 0.000 claims description 6
- 235000019786 weight gain Nutrition 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 claims description 5
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 claims description 5
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 claims description 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 4
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 4
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 4
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 4
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims description 4
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims description 4
- 102100027840 Acyl-CoA wax alcohol acyltransferase 1 Human genes 0.000 claims description 4
- 229940123208 Biguanide Drugs 0.000 claims description 4
- 108010018763 Biotin carboxylase Proteins 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 108091008794 FGF receptors Proteins 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 4
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 4
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 4
- 101000698136 Homo sapiens Acyl-CoA wax alcohol acyltransferase 1 Proteins 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 102100023418 Ketohexokinase Human genes 0.000 claims description 4
- 108010062852 Ketohexokinase Proteins 0.000 claims description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 4
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 claims description 4
- 208000035180 MODY Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 claims description 4
- 108090000192 Methionyl aminopeptidases Proteins 0.000 claims description 4
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims description 4
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 claims description 4
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 4
- 206010036069 Polydipsia psychogenic Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 4
- 102100029795 Sodium-dependent glucose transporter 1 Human genes 0.000 claims description 4
- 101710181093 Sodium-dependent glucose transporter 1 Proteins 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000021017 Weight Gain Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 238000011374 additional therapy Methods 0.000 claims description 4
- 229940125708 antidiabetic agent Drugs 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims description 4
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000000231 psychogenic polydipsia Diseases 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 201000002859 sleep apnea Diseases 0.000 claims description 4
- 230000005586 smoking cessation Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 108091006277 SLC5A1 Proteins 0.000 claims description 3
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims description 3
- 238000002483 medication Methods 0.000 claims description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000011727 Caspases Human genes 0.000 claims description 2
- 108010076667 Caspases Proteins 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 101800001982 Cholecystokinin Proteins 0.000 claims description 2
- 102100025841 Cholecystokinin Human genes 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 2
- 108010001517 Galectin 3 Proteins 0.000 claims description 2
- 102100039558 Galectin-3 Human genes 0.000 claims description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims description 2
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 claims description 2
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims description 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims description 2
- 101150113964 MPK5 gene Proteins 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 2
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 claims description 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims description 2
- 108091006299 SLC2A2 Proteins 0.000 claims description 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 229960004733 albiglutide Drugs 0.000 claims description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 230000003579 anti-obesity Effects 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims description 2
- 229960002837 benzphetamine Drugs 0.000 claims description 2
- 150000004283 biguanides Chemical class 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 claims description 2
- 108091022863 bile acid binding Proteins 0.000 claims description 2
- 102000030904 bile acid binding Human genes 0.000 claims description 2
- 229940107137 cholecystokinin Drugs 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960004890 diethylpropion Drugs 0.000 claims description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 229960005175 dulaglutide Drugs 0.000 claims description 2
- 108010005794 dulaglutide Proteins 0.000 claims description 2
- 230000008694 endothelial dysfunction Effects 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 102000004241 human proIslet peptide Human genes 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 108010004367 lixisenatide Proteins 0.000 claims description 2
- 229960001093 lixisenatide Drugs 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000001071 malnutrition Effects 0.000 claims description 2
- 235000000824 malnutrition Nutrition 0.000 claims description 2
- 229950004994 meglitinide Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 150000006636 nicotinic acid Chemical class 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960000436 phendimetrazine Drugs 0.000 claims description 2
- 229960003562 phentermine Drugs 0.000 claims description 2
- 230000037081 physical activity Effects 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 108700027806 rGLP-1 Proteins 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 229950011186 semaglutide Drugs 0.000 claims description 2
- 108010060325 semaglutide Proteins 0.000 claims description 2
- 239000003762 serotonin receptor affecting agent Substances 0.000 claims description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 108010048573 taspoglutide Proteins 0.000 claims description 2
- 229950007151 taspoglutide Drugs 0.000 claims description 2
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 229960002911 zonisamide Drugs 0.000 claims description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000012491 analyte Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/087776 | 2020-04-29 | ||
| CN2020087776 | 2020-04-29 | ||
| CN2020105865 | 2020-07-30 | ||
| CNPCT/CN2020/105865 | 2020-07-30 | ||
| PCT/CN2021/090645 WO2021219019A1 (en) | 2020-04-29 | 2021-04-28 | Heterocyclic glp-1 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524493A JP2023524493A (ja) | 2023-06-12 |
| JPWO2021219019A5 true JPWO2021219019A5 (zh) | 2024-05-10 |
Family
ID=78331790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566337A Pending JP2023524493A (ja) | 2020-04-29 | 2021-04-28 | ヘテロ環ｇｌｐ－１アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230295154A1 (zh) |
| EP (1) | EP4143183A4 (zh) |
| JP (1) | JP2023524493A (zh) |
| CN (1) | CN115667250A (zh) |
| TW (1) | TW202206429A (zh) |
| WO (1) | WO2021219019A1 (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| WO2022028572A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20240217966A1 (en) | 2021-03-24 | 2024-07-04 | Shionogi & Co., Ltd. | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| IL310400A (en) * | 2021-08-04 | 2024-03-01 | Shanghai Hansoh Biomedical Co Ltd | Modulating cycloalkyne derivative preparation method for this, as well as this application |
| CN118215478A (zh) | 2021-09-08 | 2024-06-18 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| CA3236708A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| WO2024063143A1 (ja) * | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024131869A1 (en) * | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63849B9 (sr) | 2016-12-16 | 2023-06-30 | Pfizer | Agonisti glp-1 receptora i njihova upotreba |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| RU2765721C1 (ru) * | 2018-06-15 | 2022-02-02 | Пфайзер Инк. | Агонисты glp-1 рецептора и их применение |
-
2021
- 2021-04-28 TW TW110115444A patent/TW202206429A/zh unknown
- 2021-04-28 WO PCT/CN2021/090645 patent/WO2021219019A1/en unknown
- 2021-04-28 CN CN202180031553.1A patent/CN115667250A/zh active Pending
- 2021-04-28 US US17/921,964 patent/US20230295154A1/en active Pending
- 2021-04-28 JP JP2022566337A patent/JP2023524493A/ja active Pending
- 2021-04-28 EP EP21795712.5A patent/EP4143183A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021219019A5 (zh) | ||
| JPWO2021160127A5 (zh) | ||
| Bansal et al. | An overview on medicinal perspective of thiazolidine-2, 4-dione: A remarkable scaffold in the treatment of type 2 diabetes | |
| US11801316B2 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
| TWI819518B (zh) | Glp-1r調節化合物 | |
| JPWO2022028572A5 (zh) | ||
| EP1846035B1 (en) | Combination therapy | |
| US20230201185A1 (en) | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| CA2928028A1 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
| KR20170123658A (ko) | 장 수용체를 활성화시키는 파네소이드 x 수용체 작용제를 사용한 성인 잠복성 자가면역 당뇨병의 치료 | |
| JP2009501776A (ja) | 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 | |
| JP2007538014A (ja) | 活性薬剤を送達するためのアリールケトン化合物および組成物 | |
| JPWO2021155841A5 (zh) | ||
| JPWO2011002001A1 (ja) | ピラゾール誘導体とビグアナイド薬との組み合わせ医薬 | |
| EA024207B1 (ru) | Пиразольные соединения | |
| JPWO2022042691A5 (zh) | ||
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| JP2019519478A (ja) | ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法 | |
| US7081473B2 (en) | Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient | |
| US20200087258A1 (en) | Inhibitor of citrate transporter and their use in therapy | |
| JPWO2022225914A5 (zh) | ||
| JPWO2022048665A5 (zh) | ||
| JP2024523945A (ja) | 血糖値の管理方法ならびに糖尿病及び関連状態の治療 | |
| KR20070008706A (ko) | 피롤리딘 유도체 | |
| WO2011002011A1 (ja) | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |